Nav: Home

£1.5 million trial to prevent fractures in people with brittle bone disease

January 16, 2017

People with a rare bone condition that can cause them to have hundreds of fractures during a lifetime are being invited to trial a potential treatment.

Researchers have received £1.5 million to conduct the study, which will involve 390 people with a condition called Osteogenesis Imperfecta (OI).

The six-year trial will test whether the combination of two therapies that are already used to treat a different bone condition can also help to reduce the risk of fractures in people with OI.

Around half of the study's participants will be treated with a drug called teriparatide followed by treatment with another drug called zoledronic acid. The other half will receive standard care.

Researchers will track the participants for up to five years to see whether the combination of therapies offers any benefit.

Osteogenesis Imperfecta is caused by genetic mutations that lead to abnormalities in an important component of bone called collagen. People with the disease have extremely fragile bones that break easily, often from mild trauma or for no apparent cause.

Both teriparatide and zoledronic acid are established treatments for the bone-thinning disease osteoporosis but this is the first time they have been tested in combination as therapies for OI.

The study, led by the University of Edinburgh, will involve 25 hospitals in the UK and one in the Republic of Ireland. It is being funded by The National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme.

Professor Stuart Ralston, of the University of Edinburgh's Centre for Genomic and Experimental Medicine, said: "This is potentially a game-changing trial since it is the first study that had been specifically designed to investigate whether any treatment can prevent fractures in osteogenesis imperfecta. If the results are positive, it could herald a new dawn in the treatment of this rare but devastating condition."

Chief Executive of the UK Charity Brittle Bone Society, Patricia Osborne, said "We have been supporting people with OI for 50 years and are pleased to see a potential new therapy being trialled that may improve the quality of peoples' lives".
-end-


University of Edinburgh

Related Disease Articles:

Contact sports associated with Lewy body disease, Parkinson's disease symptoms, dementia
There is mounting evidence that repetitive head impacts from contact sports and other exposures are associated with the neurodegenerative disease chronic traumatic encephalopathy (CTE) and dementia.
In kidney disease patients, illicit drug use linked with disease progression and death
Among individuals with chronic kidney disease, hard illicit drug use was associated with higher risks of kidney disease progression and early death.
Parkinson's disease among patients with inflammatory bowel disease
Patients with inflammatory bowel disease appeared more likely than patients without the disorder to develop Parkinson's disease, while anti-tumor necrosis factor therapy for inflammatory bowel disease was associated with reduced incidence of Parkinson's in a new study that analyzed administrative claims data for more than 170 million patients.
Despite reductions in infectious disease mortality in US, diarrheal disease deaths on the rise
Deaths from infectious diseases have declined overall in the United States over the past three decades.
Defects on regulators of disease-causing proteins can cause neurological disease
Mutations in human PUMILIO1, a gene that regulates Ataxin1 production, cause conditions similar to spinocerebellar ataxia type 1 (SCA1).
Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study in The Lancet suggests, paving the way for further research to define its efficacy and safety.
Findings support role of vascular disease in development of Alzheimer's disease
Among adults who entered a study more than 25 years ago, an increasing number of midlife vascular risk factors, such as obesity, high blood pressure, diabetes, high cholesterol and smoking, were associated with elevated levels of brain amyloid (protein fragments linked to Alzheimer's disease) later in life, according to a study published by JAMA.
Dietary factors associated with substantial proportion of deaths from heart disease, stroke, and disease
Nearly half of all deaths due to heart disease, stroke, and type 2 diabetes in the US in 2012 were associated with suboptimal consumption of certain dietary factors, according to a study appearing in the March 7 issue of JAMA.
Study links changes in oral microbiome with metabolic disease/risk for dental disease
A team of scientists from The Forsyth Institute and the Dasman Diabetes Institute in Kuwait have found that metabolic diseases, which are characterized by high blood pressure, high blood sugar, and obesity -- leads to changes in oral bacteria and puts people with the disease at a greater risk for poor oral health.
Fatty liver disease contributes to cardiovascular disease and vice versa
For the first time, researchers have shown that a bi-directional relationship exists between fatty liver disease and cardiovascular disease.
More Disease News and Disease Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.